Clinical trial
Efficacy and Safety/Tolerability of Ragweed MATA MPL
NCT00423787 · Allergy Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00423787 |
|---|---|
| Title | Efficacy and Safety/Tolerability of Ragweed MATA MPL |
| Official title | Efficacy and Safety/Tolerability of Ragweed MATA MPL, a Randomized, Placebo-Controlled, Double-Blind Study |
| Lead sponsor | Allergy Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type I Hypersensitivity |
| Intervention type | Biological |
| Interventions | Ragweed MATA MPL |
| Enrollment | 993 |
| Start date | Mar 1, 2007 |
| Primary completion | Nov 1, 2007 |
| Completion | Mar 1, 2008 |
| First posted | Jan 18, 2007 |
| Last update posted | Jun 17, 2010 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: